Viking Therapeutics (VKTX) Corporate presentation summary

Strategic focus and pipeline

• Advancing novel therapeutics for metabolic and endocrine diseases, with multiple programs showing best-in-class efficacy data.

• Lead asset VK2735, a dual GLP-1/GIP agonist, is in Phase 3 for obesity, with both injectable and oral formulations in late-stage development.

• VK3019 (amylin agonist) is in Phase 1 for obesity; VK2809 and VK0214 target MASH and X-ALD, respectively, with positive Phase 2b and 1b results.

VK2735 clinical results and development

• VK2735 demonstrates superior pharmacokinetics and up to 40% greater weight loss in primate models compared to tirzepatide.

• Oral VK2735 achieved up to 8.2% weight loss at 28 days and 12.2% at 13 weeks in Phase 1/2, with effects maintained post-treatment.

• Subcutaneous VK2735 showed up to 15% weight loss at 13 weeks in Phase 2, with durable effects and no plateau observed.

• Exploratory cohorts indicate lower maintenance doses can sustain or extend weight loss.

Safety and tolerability

• Across oral and injectable studies, 92–99% of adverse events were mild to moderate, mainly GI-related and transient.

• GI side effects (nausea, vomiting, diarrhea, constipation) were dose-dependent and typically resolved over time.

• Tolerability profiles suggest potential for optimized titration and maintenance regimens.